Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
Eli Lilly reported higher net income and revenue in the recent quarter, fueled by continued surging demand for its GLP-1 weight-loss drugs.
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-quarter profit.
GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
Many investors share the quality of being curious. That lends itself to viewing the world in a particular way and making connections that others can overlook.
Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO), arguing that the market's reaction to a failed heart drug trial looks somewhat overdone while flagging deeper concerns about pricing and competition in obesity. The Danish group announced that ziltevekimab, an anti-inflammatory antibody targeting the protein interleukin-6, missed the primary endpoint of its ZEUS trial.
As Americans go direct with GLP-1 prescriptions, Walmart, Costco, Amazon will be big weight-loss winners
As employers drop GLP-1 coverage, more Americans are being encouraged to use direct-to-consumer (DTC) weight-loss drug prescription programs. Major retailers and pharmacy chains, from CVS to Walmart and Costco, are racing to fill the void and gain market share, moves that could punish independent pharmacies.
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
Shipping and logistics companies are tapping into the growing healthcare market as cold chain and temperature-controlled facilities become more crucial. Those companies are investing millions of dollars and strengthening dozens of facilities to meet the evolving needs of shipping pharmaceuticals.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may boost demand for treatments like fillers and anti-wrinkle injections.
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.
GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk
LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker's rival injections. Novo Nordisk is specifically taking issue with nationwide ads that cite what it called "outdated" clinical trials to compare the highest doses of Lilly's medicines to lower doses of Novo's drugs.
